Меню
Набор скоро начнётся NCT06823999

Prevention and Treatment for Bruises in Patients With Ischemic Stroke

Фаза IV С лечением Stroke Bruises Skin Lesions

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Ascorbic acid (Vitamin C), Normal Saline (Placebo).
Кому может быть актуально
Состояния в реестре: Stroke, Bruises, Skin Lesions. Базовые параметры: 20 лет — 85 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Effect of Vitamin C in the Prevention and Treatment for Bruises in Patients With Ischemic Stroke: A Double-blind Randomized Control Trial

Обзор

Background Over the past few decades, significant advances have been made in the diagnosis and treatment of strokes. Most studies focus on functional recovery in stroke patients. In addition to motor function, there are many symptoms may affect function and quality of life in stroke patients. Bruises are caused by damage to the skin that causes blood to drain out of the capillaries and accumulate in the connective tissue of the skin or subcutaneous tissue. The study on non-motor syndrome in ischemic stroke patients found that 25.8% of ischemic stroke patients had bruises and 17.7% of bruises were unexplained bruises. In addition to the physiological and emotional effects on stroke patients, bruises may increase infection risk and affect stroke patient outcomes. Vitamin C is a natural antioxidant discovered in 1747 to treat and prevent scurvy. Vitamin C can reduce gum bleeding and prevent colon bleeding after a polypectomy. Vitamin C has been reported to reduce brain edema around brain injury and decrease mortality in patients with traumatic brain injury. Dehydroascorbic acid decreases infarct volume in mice with middle cerebral artery occlusion. Investigators hypothesized that administration of vitamin C to patients with acute ischemic stroke patients would decrease the risk of bleeding and enhance its resolution. Investigators also hypothesized that vitamin C injection could minimize infarct volume and improve outcomes in ischemic stroke patients. The aims of the study include: 1. To investigate whether vitamin C injections can reduce bruising risk and enhance bruising resolution. 2. To explore whether vitamin C injections in the acute phase of stroke can improve the prognosis of ischemic stroke patients. Methods This is a prospective, double-blind, randomized controlled study. All patients admitted to the hospital under the diagnosis of ischemic stroke and stroke was confirmed by Magnetic Resonance imaging (MRI) or brain computed imaging (CT) and aged between 20 and 85 years were invited to participate in the study. Investigators excluded patients who had these diseases: cancer receiving chemotherapy, end stage renal disease receiving dialysis, autoimmune disease, hematological disease, Glucose-6-phosphatase disease, gouty arthritis, and a lack of informed consent. During the study period, all patients who met the inclusion and exclusion criteria were invited to participate in the study. After informed consent, participants were randomly assigned to the experimental group or the control group. All participants underwent NIHSS evaluation and a detailed dermatological examination on the day of hospitalization. After enrollment, the experimental group received 4 mg Vitamin C injection per day for 4 days, while the control group received the same volume of normal saline injection per day for 4 days. Researchers evaluate participant skin condition (including bruises number and size, color) every day during hospitalization, and up to 1 month after stroke. Investigators evaluate NIHSS at discharge and follow-up functional outcome (mRS) up to 3 months after stroke onset. Analysis Rate shows bruise percentage. Chi square or Fisher exact test was applied to compare the difference in bruises between two groups. Logistic regression was used to compare bruise risk between groups. Wilcoxon rank sign test was used to analyze stroke severity and outcome between two groups.

Подробное описание

Introduction

Background Stroke is one of the most severe diseases that causes mortality and morbidity. With the latest advances in stroke prevention and treatment, stroke incidence and mortality have significantly reduced. Advances in imaging technology have improved ischemic stroke diagnosis. The establishment of a stroke center and the improvement of procedures will allow stroke patients to be treated faster. Advances in medical technology include advances in imaging technology, endovascular thrombectomy(1, 2), and advances in pharmaceuticals include tissue plasminogen activator(3), anticoagulant(4), and antiplatelet drugs(5) lead to better outcomes for stroke patients. Current research on stroke focuses on motor function treatment. However, besides reduced limb strength, stroke patients still have many symptoms that deserve attention. Although these diseases do not directly affect motor function, they will cause physical and psychological obstacles and affect stroke patients' quality of life. For example, depression, post-stroke pain, sleep disorders, bedsores, bruises, and infection, are all common problems after a stroke and deserve attention. In addition to limb weakness in stroke patients, the occurrence of the above-mentioned conditions will prolong hospitalization time, increase hospitalization expenses, and affect treatment results. The more common problems are post-infarction bleeding, infection, and stroke. Stroke patients also often suffer from non-neurological complications, which affect patient treatment outcomes and neurological recovery (6). Common complications include cardiovascular diseases, pulmonary embolism, sleep disorders, pain, falls, venous thrombosis, infections, and bleeding. Bruising is an often- clinical issue caused by blood leaking from blood vessels and accumulating in the tissue beneath the skin. The most common cause of bruising is blunt force trauma, which leads to subcutaneous vascular rupture and blood leakage. Other common causes include drug injections, the underlying disease, or treatment for the disease. Age is also a factor influencing bruising. In elderly individuals, skin degeneration results in a thinner epidermis, fragile blood vessels, and reduced subcutaneous tissue, making them more prone to bruising (7).

Elderly patients often have more medical conditions, increasing bruising. Medications such as antithrombotic and anticoagulant drugs also heighten bruising risk. Bruising can also result from vitamin deficiencies (8). Although most bruises fade over time, with color changing during the process, the timing of the bruise cannot be accurately determined by color changes, as the rate of resolution varies among individuals (9). However, bruises may sometimes indicate more severe underlying conditions (10).

For instance, abdominal bruising found might be a sign of internal bleeding. Bruising around the mastoid region or behind the ear may indicate skull fractures. Bruising in the scrotum, perineum, or anterior abdomen wall may suggest abdominal aortic rupture (11). In addition to being associated with severe diseases, bruising also increases infection risk and affects patient recovery (12).

If bruising is observed in children, especially in those who are not capable of moving on their own, abuse should be considered. Research indicates that bruising in infants is a potential marker of abuse and warrants attention. While the causes of bruises in older adults differ from those in children, unexplained bruising in the elderly also requires investigation, as elder abuse remains a concern. Bruising in older individuals may also be the result of abuse (13).

The hospital's research team found that 25.8% of stroke patients exhibit bruising. This is with 55.4% of cases occurring before hospitalization and 44.6% during hospitalization. Of these, 17.7% of bruises are unknown. These unexplained bruises could be due to minor injuries that patients are unaware of, concealment, abuse, other underlying diseases, or medication-related causes, all of which merit further investigation.

However, beyond investigating bruising causes, the most crucial steps are to treat existing bruises and prevent further occurrences. Previous research on bruising focuses on its prevention and treatment after surgery. To date, there is still no simple and effective method to prevent bruising (14).

Vitamin C is a natural vitamin. As early as 1747, the connection between scurvy and vitamin C was suspected and the first use of a randomized controlled trial was conducted to study this relationship. In the experiment, 12 scurvy patients were divided into two groups: six in the experimental group consumed foods high in vitamin C, while the control group did not. The results showed that scurvy patients who consumed vitamin C-rich foods recovered quickly, while those who did not showed no improvement.

Vitamin C is an essential cofactor for enzymes and a powerful antioxidant. It plays a critical role in synthesizing neurotransmitters, collagen, and maintaining endothelial cell function (15). An adult non-smoker typically has about 1.5 grams of vitamin C in their body, consuming about 60 milligrams daily. Smokers consume more vitamin C, approximately 140 milligrams per day. In cases of illness, such as surgery, trauma, infection, or shock, blood levels of vitamin C drop rapidly, requiring supplementation through injection (16).

Stroke patients have lower vitamin C blood concentrations than healthy individuals. Vitamin C protects neurons and reduces ischemic damage.

Vitamin C protects blood vessels. Research indicates that in patients undergoing colorectal polyp removal, administering 500 mg of vitamin C two hours before the procedure significantly reduces the post-polypectomy bleeding rate (17).

A comprehensive study found that supplementing vitamin C in individuals with low blood levels reduces the incidence of gum bleeding and retinal hemorrhages (18). Previous research showed that administering high doses of vitamin C to patients with severe brain injuries decreases the extent of brain edema around the injury site and lowers mortality rates (19).

Previous studies demonstrated that high-dose vitamin C enhances critically ill patients' response to vasopressors, preserves endothelial barrier function, prevents cell apoptosis, and increases recovery rates after cardiopulmonary resuscitation in critically ill patients (20). However, other studies have shown that while high-dose vitamin C in sepsis patients reduces vasopressor use and the rate of acute organ failure, it does not lower mortality rates (21).

A study found that patients with atrophic gastritis who took high doses of vitamin C (500 mg daily) over an extended period, compared to those taking 50 mg daily, had significantly reduced levels of reactive oxygen species (ROS), which are aging and cancer-inducing factors, in their blood (22). Long-term use of vitamin C reduces oxidative stress, decreases protein aggregation in the brain, and may help mitigate neurodegenerative diseases.

Vitamin C is a safe and inexpensive medication, and it is safe beyond doubt. In an animal study by Judy et al., it was found that in rats experiencing middle cerebral artery occlusion followed by reperfusion, administering oxidized vitamin C reduced the infarct size by 53% to 59% (23). In an animal experiment, rats were subjected to middle cerebral artery occlusion for 60 minutes, followed by reperfusion for 30 or 60 minutes. Rats injected with vitamin C had higher blood levels of Ten eleven translocase and 5-hydroxymethylcytosine than those not injected with vitamin C, and the infarct size was smaller (24). Stroke patients aged 65 and older with higher blood concentrations of vitamin C had a 50% reduced mortality rate than those with low concentrations (25). In comparison to healthy adults, stroke patients had lower blood concentrations of vitamin C, and increased levels of inflammatory markers (CRP, ICAM-1, MCP-1), and increased oxidative stress (8-epiPGF2), indicating an inflammatory response in stroke patients (26). A meta-analysis found that individuals who consumed more vitamin C and had higher blood concentrations of vitamin C had a lower risk of stroke (27).

Based on previous research showing that high-dose vitamin C injections can decrease bleeding rates during colorectal polyp removal (17) and decrease the incidence of gum and retinal bleeding (18), the first hypothesis of this study is that vitamin C has a protective effect on blood vessels. It may aid in vascular repair, reduce bruising, and accelerate bruise recovery. Since high-dose vitamin C has been shown to reduce brain ischemia (15, 28), the second hypothesis is that acute stroke patients have low blood vitamin C levels. Vitamin C injections can improve micro-vascular blood flow in the brain, aiding stroke patients' recovery (29).

Beyond its visual impact, bruising can also affect psychologically (30), increase the risk of infection, influence patient outcomes (12, 31), and impact physicians' medication choices. Currently, there is limited research on bruising in stroke patients, and few studies explore the relationship between vitamin C and ischemic stroke. This study aims to enhance understanding of the impact of bruising in stroke patients, its prevention and treatment, and the effects of vitamin C on stroke outcomes.

Methods This study was approved by the Institutional Review Board (IRB) of Chia Yi Christian Hospital (Approval Number: IRB2024099). The research subjects were ischemic stroke patients at Chia Yi Christian Hospital.

A. Study Design: This study adopted a parallel design, enrolling hospitalized ischemic stroke patients confirmed by computed tomography (CT) or magnetic resonance imaging (MRI). Patients meeting any exclusion criteria for the study were not included. During the study, participants could withdraw at any time upon request. If adverse drug reactions occurred during the study, the principal investigator could terminate the patient's participation.

To investigate the incidence, causes, and impact of hematoma on stroke patients' treatment outcomes, this study observed and recorded the timing, quantity, resolution time, and resolution rate of hematoma. In addition, it recorded its causes. To explore whether hematoma occurrence could be reduced and recovery accelerated, and to improve stroke patients' treatment outcomes, a double-blind, randomized study design was used. This study focuses on bleeding issues related to stroke patients. It explores the causes and impacts of bruising on treatment outcomes and stroke recurrence, and examines methods of bruising prevention and treatment.

B. Randomized Assignment Randomization was conducted using the National Cancer Institute Clinical Trial Tool (NIH \> National Cancer Institute Clinical Trial Tool). Participants were randomly assigned to either the experimental or the control group. The experimental group received daily injections of 4 grams of vitamin C, while the control group received injections of an equivalent volume of normal saline.

C. Participants:

1. Number of Participants (Sample Size):

The sample size was estimated using G-power. With an alpha error of 0.05, a power of 0.95, and an effect size of 0.2, at least 314 participants were required. This study plans to recruit 400 participants, with 200 in the experimental group and 200 in the control group.

The evaluation metric is the occurrence of newly formed hematomas during hospitalization. 2. Recruitment of Potential Participants (Target Population, Methods, Locations, etc.):

The recruitment target comprises patients with acute ischemic stroke. Physicians and research assistants from the research team will explain the study's purpose and methods to patients on the stroke ward. Upon consent, the study will proceed.

E. Implementation Methods:

1. The execution process:

After confirmation of ischemic stroke via c

Вмешательства

  • Препарат Ascorbic acid (Vitamin C)
    In the study, acute ischemic stroke patients will receiving vitamin C 4 gram perday for 4 days.
  • Другое Normal Saline (Placebo)
    Particiapnts receiving normal saline 20 ml perday for 4 days

Первичные конечные точки

  • 1. The rate of hematoma occurrence (in any location). 2. Comparison of hematoma resolution rates, using a benchmark of a reduction in hematoma area greater than 30%. This applies to both pre-existing and newly developed hematomas. [Срок оценки: The study will begin at Auguest 1, 2025, we evaluate patients skin condition everyday and analysis the results at August 2027.]

Критерии участия

Критерии включения

  • Ischemic stroke patients.
  • Aged 20 to 85 years.

Критерии исключения

  • o Cancer patients undergoing chemotherapy.
  • End-stage renal disease patients receiving hemodialysis.
  • Patients undergoing immunosuppressive therapy.
  • Patients with coagulation disorders.
  • Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (favism).
  • Patients with thalassemia.
  • Patients who did not sign the consent form.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Четверное слепое
Основная цель
Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Публикации

  • Sarraj A, Hassan AE, Abraham MG, Ortega-Gutierrez S, Kasner SE, Hussain MS, Chen M, Blackburn S, Sitton CW, Churilov L, Sundararajan S, Hu YC, Herial NA, Jabbour P, Gibson D, Wallace AN, Arenillas JF, Tsai JP, Budzik RF, Hicks WJ, Kozak O, Yan B, Cordato DJ, Manning NW, Parsons MW, Hanel RA, Aghaebrahim AN, Wu TY, Cardona-Portela P, Perez de la Ossa N, Schaafsma JD, Blasco J, Sangha N, Warach S, G PMID 36762865
  • Veunac L, Saliou G, Knebel JF, Bartolini B, Puccinelli F, Michel P, Hajdu SD. Revascularization of carotid artery occlusion using stenting versus non stenting in endovascular management of tandem occlusion stroke. J Clin Neurosci. 2022 Apr;98:15-20. doi: 10.1016/j.jocn.2022.01.036. Epub 2022 Feb 4. PMID 35131720
  • Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998 Oct 17;352(9136):1245-51. doi: 10.1016/s0 PMID 9788453
  • Essebag V, Healey JS, Joza J, Nery PB, Kalfon E, Leiria TLL, Verma A, Ayala-Paredes F, Coutu B, Sumner GL, Becker G, Philippon F, Eikelboom J, Sandhu RK, Sapp J, Leather R, Yung D, Thibault B, Simpson CS, Ahmad K, Toal S, Sturmer M, Kavanagh K, Crystal E, Wells GA, Krahn AD, Birnie DH. Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma: Combin PMID 31610718
  • Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19;379(3):215-225. doi: 10.1056/NEJMoa1800410. Epub 2018 May 16. PMID 29766750
  • Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol. 2010 Jan;9(1):105-18. doi: 10.1016/S1474-4422(09)70266-2. PMID 20083041
  • Sinikumpu SP, Jokelainen J, Haarala AK, Keranen MH, Keinanen-Kiukaanniemi S, Huilaja L. The High Prevalence of Skin Diseases in Adults Aged 70 and Older. J Am Geriatr Soc. 2020 Nov;68(11):2565-2571. doi: 10.1111/jgs.16706. Epub 2020 Aug 4. PMID 32754902
  • Pahadiya HR, Lakhotia M, Choudhary S, Prajapati GR, Pradhan S. Reversible ecchymosis and hyperpigmented lesions: A rare presentation of dietary Vitamin B12 deficiency. J Family Med Prim Care. 2016 Apr-Jun;5(2):485-487. doi: 10.4103/2249-4863.192343. PMID 27843871

Идентификаторы

NCT: NCT06823999 · IRB2024099

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗